Paper Details

  1. Home
  2. Paper Details

Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.

Author: BrownKimberly A, BrownRobert S, FontanaRobert J, LevitskyJosh, RubinRaymond A, RussoMark W, VargasHugo, YoshidaEric M

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Telaprevir combination therapy for posttransplant hepatitis C virus infection yielded superior efficacy than historical controls (61% achieved sustained virologic response). Adverse events were similar to, but exceeded, those in immunocompetent patients.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Our objective was to determine the safety, efficacy, and pharmacokinetics of telaprevir plus pegylated interferon alfa 2a and ribavirin for chronic, posttransplant genotype 1 hepatitis C virus infection. MATERIALS AND METHODS: A prospective, single-arm, multicenter, open-label, phase 2b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.6002/ect.2016.0251

データ提供：米国国立医学図書館（NLM）

Telaprevir for Post-transplant Hepatitis C: A Safety and Efficacy Study

Hepatitis C virus (HCV) infection can pose significant challenges, especially in the context of organ transplantation. This study examines the safety, efficacy, and pharmacokinetics of telaprevir, a protease inhibitor, in combination with pegylated interferon alfa 2a and ribavirin for treating post-transplant genotype 1 HCV infection.

Telaprevir Shows Promise for Post-transplant HCV

The study found that telaprevir combination therapy yielded superior efficacy compared to historical controls in treating post-transplant HCV. The study's results provide evidence for the potential of telaprevir as a valuable treatment option for this challenging condition. While adverse events were similar to those seen in immunocompetent patients, the study also found that telaprevir treatment led to substantial reductions in calcineurin inhibitor dosing levels.

Navigating Treatment Options for HCV

The study's findings offer valuable insights into the use of telaprevir in treating post-transplant HCV. The research highlights the importance of carefully considering the potential risks and benefits of telaprevir combination therapy. The study's findings can guide clinicians in making informed decisions about treatment strategies for HCV patients, particularly those who have undergone transplantation.

Dr.Camel's Conclusion

This study provides a detailed examination of the safety, efficacy, and pharmacokinetics of telaprevir for treating post-transplant genotype 1 HCV infection. The research highlights the potential of telaprevir combination therapy as a promising treatment option for this challenging condition, with notable improvements in efficacy compared to historical controls. The study's findings offer valuable guidance for clinicians and researchers seeking to optimize treatment strategies for HCV patients, particularly those who have undergone organ transplantation.

Date :
  1. Date Completed 2018-10-03
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27855589

DOI: Digital Object Identifier

10.6002/ect.2016.0251

Related Literature

Article Analysis
・Effects of telaprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.